Simulations Plus acquired by Altaris for $18.50/share
Simulations Plus, Inc., a developer of model-informed and AI-accelerated drug development software, has been acquired by Altaris, LLC, an investment firm focused on the healthcare industry. The transaction, originally announced on June 16, 2026, values the company at $18.50 per share in cash. Simulations Plus will now